Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Heart failure (HF) affects up to over 20% of patients with type 2 diabetes (T2DM), even more in the elderly. Although, in T2DM, both hyperglycemia and the proinflammatory status induced by insulin resistance are crucial in cardiac function impairment, SGLT2i cardioprotective mechanisms against HF are several. In particular, these beneficial effects seem attributable to the significant reduction of intracellular sodium levels, well-known to exert a cardioprotective role in the prevention of oxidative stress and consequent cardiomyocyte death. From a molecular perspective, patients’ exposure to gliflozins’ treatment mimics nutrient and oxygen deprivation, with consequent autophagy stimulation. This allows to maintain the cellular homeostasis through different degradative pathways. Thus, since their introduction in the clinical practice, the hypotheses on SGLT2i mechanisms of action have changed: from simple glycosuric drugs, with consequent glucose lowering, erythropoiesis enhancing and ketogenesis stimulating, to intracellular sodium-lowering molecules. This provides their consequent cardioprotective effect, which justifies its significant reduction in CV events, especially in populations at higher risk. Finally, the updated clinical evidence of SGLT2i benefits on HF was summarized. Thus, this review aimed to analyze the cardioprotective mechanisms of sodium glucose transporter 2 inhibitors (SGLT2i) in patients with HF, as well as their clinical impact on cardiovascular events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
NF-κB signaling in inflammation
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.23 · Cited by 8,791 · cited 2×
“Similar findings were also observed as for NF-κB and IL-6 in the renal tissues of diabetic mice and IL-6 and C-reactive protein (CRP) in hepatic cells and adipocytes of obese mice subjected Int.”
BackgroundCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · cited 7×
“Four large CV outcome studies have recently been completed: EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58 and VERTIS-CV [110,113,157,158].”
BackgroundMethodInfluentialCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206 · cited 14×
“The DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) study was instead the first international, multicenter, parallel-group, randomized, doubleblind clinical trial on a SGLT2i designed to assess the effect of Dapagliflozin 10 mg (oncedaily, in addition to the standard care) vs. a placebo in…”
BackgroundInfluentialCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness
Vlachopoulos, C., Aznaouridis, K., & Stefanadis, C. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.061 · Cited by 4,165 · cited 1×
“Moreover, the pulse wave velocity (PWV), an arterial stiffness index, decreased after 48 h of Dapagliflozin administration in a small cohort of patients with T2DM [117].”
BackgroundA Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Diabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 11×
“Secondary outcomes: death from any cause, death from CV causes, progression of albuminuria, and the composite of death from CV causes and HHF. Median follow-up: 126 weeks; mean follow-up: 188 weeks Composite of death from CV causes, nonfatal MI, or nonfatal stroke 0.86 (0.75–0.97) Death from any cause 0.87 (0.74–1.01)…”
BackgroundResultInfluentialThe ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
Youm, Y.-H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., D'Agostino, D., Planavsky, N., Lupfer, C., Kanneganti, T. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3804 · Cited by 2,172
Sotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868 · cited 1×
“In the latter setting, particularly, recent data with Sotagliflozin [167] and preliminary data with Empagliflozin have been reported [168], and further results are expected soon from the ongoing trials [169].”
ResultCardiovascular outcomes with ertugliflozin in type 2 diabetes
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004967 · Cited by 1,514 · cited 4×
“Of note, the VERTIS-CV trial had the higher proportion of patients with HF (~24”
MethodInfluentialMolecular mechanisms of diabetic cardiomyopathy
Bugger, H., & Abel, E. D. (2014) · Diabetologia · doi:10.1007/s00125-014-3171-6 · Cited by 903
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837 · cited 2×
“hydrochlorothiazide and bumetanide, respectively [125,131].”
BackgroundThe Incidence of Congestive Heart Failure in Type 2 Diabetes
Nichols, G. A., Gullion, C. M., Koro, C. E., Ephross, S. A., & Brown, J. B. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1879 · Cited by 812
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740 · cited 1×
“Besides, the observed relationship between increased hemoglobin and hematocrit levels and cardioprotection after the administration of Empagliflozin (shown in the exploratory analysis of the EMPA-REG study) was associated with a decrease in the CV mortality rate [133].”
BackgroundScirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550 · cited 1×
“These are followed by an improvement of the barrier function of the vascular system by the phosphorylation of nitric oxide endothelial synthase (eNOS) and reduction of microvascular endothelial lesions in coronary endothelial cells [145].”
BackgroundShindler, D. M., Kostis, J. B., Yusuf, S., Quinones, M. A., Pitt, B., Stewart, D., Pinkett, T., Ghali, J. K., Wilson, A. C., & The SOLVD Investigators (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89163-1 · Cited by 516 · cited 1×
“HF and T2DM, when coexistent, are associated with a worse morbidity and mortality outcome, and T2DM further represents a predictor of symptomatic HF [14].”
BackgroundChilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507
Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13126 · Cited by 499 · cited 2×
“hydrochlorothiazide and bumetanide, respectively [125,131].”
BackgroundVallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., & Rieg, T. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00520.2013 · Cited by 483
Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure
Dei Cas, A., Khan, S. S., Butler, J., Mentz, R. J., Bonow, R. O., Avogaro, A., Tschoepe, D., Doehner, W., Greene, S. J., Senni, M., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2014.08.004 · Cited by 401 · cited 1×
“The risk of HF in T2DM patients, almost double that in the general population, is affected by several risk factors [6].”
BackgroundMazer, C. D., Hare, G. M. T., Connelly, P. W., Gilbert, R. E., Shehata, N., Quan, A., Teoh, H., Leiter, L. A., Zinman, B., Jüni, P., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044235 · Cited by 371 · cited 1×
“It also triggers myocardium protection by increasing the hematocrit, with a consequent increase of the oxygen supply to the tissues [132].”
BackgroundMazidi, M., Rezaie, P., Gao, H., & Kengne, A. P. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004007 · Cited by 347
O-GlcNAc signaling: a metabolic link between diabetes and cancer?
Slawson, C., Copeland, R. J., & Hart, G. W. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.04.005 · Cited by 346 · cited 1×
“Moreover, high glucose levels are responsible for the formation of nonenzymatic advanced glycation end products (AGEs) and glucose metabolites such as b-N-acetylglucosamine, which can negatively affect cardiac contractility and relaxation by targeting Ca2þ/calmodulindependent protein kinase II, phospholamban and the m…”
BackgroundBoonman-de Winter, L. J. M., Rutten, F. H., Cramer, M. J. M., Landman, M. J., Liem, A. H., Rutten, G. E. H. M., & Hoes, A. W. (2012) · Diabetologia · doi:10.1007/s00125-012-2579-0 · Cited by 343
Zhao, Y., Xu, L., Tian, D., Xia, P., Zheng, H., Wang, L., & Chen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13101 · Cited by 333 · cited 2×
“Hyperuricemia has also been reported with HF at the preserved ejection fraction (HFpEF) in hypertensive individuals as a predictor of the incidence involved in the pathophysiological cascade of HFpEF through various proposed mechanisms [82,83].”
BackgroundResultOgawa, W., & Sakaguchi, K. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12401 · Cited by 307 · cited 1×
“A further contribution to ketogenesis also results from an increase in glucagon levels, increased as an effect secondary to the reduced insulin excretion or to alpha-pancreatic cells activity, expressing SGLT2 [68].”
BackgroundDoehner, W., Rauchhaus, M., Ponikowski, P., Godsland, I. F., von Haehling, S., Okonko, D. O., Leyva, F., Proudler, A. J., Coats, A. J. S., & Anker, S. D. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.093 · Cited by 294 · cited 1×
“HF patients are often insulin-resistant, which can, in turn, either boost diabetes onset or worsen it [11].”
BackgroundHan, J. H., Oh, T. J., Lee, G., Maeng, H. J., Lee, D. H., Kim, K. M., Choi, S. H., Jang, H. C., Lee, H. S., Park, K. S., et al. (2017) · Diabetologia · doi:10.1007/s00125-016-4158-2 · Cited by 281 · cited 3×
“A reduction in proinflammatory cytokine interleukin 6 (IL-6) was also observed, while tumor necrosis factor α (TNF-α) was not affected [89].”
BackgroundKario, K., Okada, K., Kato, M., Nishizawa, M., Yoshida, T., Asano, T., Uchiyama, K., Niijima, Y., Katsuya, T., Urata, H., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037076 · Cited by 251 · cited 1×
“The direct cardiac effects of SGLT2i include an improvement both of the preload, secondary to natriuresis and osmotic diuresis, and of the afterload, secondary to the reduction of sodium and circulating volume, through the reduction of both systolic and diastolic blood pressure (3–5 mmHg and 2 to 3 mmHg, respectively)…”
BackgroundCosentino, F., Cannon, C. P., Cherney, D. Z. I., Masiukiewicz, U., Pratley, R., Dagogo-Jack, S., Frederich, R., Charbonnel, B., Mancuso, J., Shih, W. J., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.050255 · Cited by 242
Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
Matthews, V. B., Elliot, R. H., Rudnicka, C., Hricova, J., Herat, L., & Schlaich, M. P. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001434 · Cited by 222
Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD
Schneider, M. P., Raff, U., Kopp, C., Scheppach, J. B., Toncar, S., Wanner, C., Schlieper, G., Saritas, T., Floege, J., Schmid, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060662 · Cited by 195 · cited 1×
“As a result, there is a reduction in the plasma volume and total body sodium content [128], with consequent alterations of the cardiac preload conditions, positively affecting the left ventricular Franklin-Starling curve [129,130].”
BackgroundLee, P. C., Ganguly, S., & Goh, S. ‐. (2018) · Obesity Reviews · doi:10.1111/obr.12755 · Cited by 189 · cited 1×
“Such a finding suggests that, after achieving the lower limits of the SGLT2i clinical efficacy, the initial weight lowering begins to slow down until a plateau phase [99].”
BackgroundObesity-Related Heart Failure With a Preserved Ejection Fraction
Packer, M., & Kitzman, D. W. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.01.009 · Cited by 172 · cited 1×
“In these patients, IR and proinflammatory cytokines released by hypertrophic visceral adipocytes cause arterial stiffness, endothelial dysfunction in the arterioles and a reduction in capillary density at the systemic level and of the heart, thus increasing the cardiac afterload [107,108].”
BackgroundPredictors of heart failure among women with coronary disease
Bibbins-Domingo, K., Lin, F., Vittinghoff, E., Barrett-Connor, E., Hulley, S. B., Grady, D., & Shlipak, M. G. (2004) · Circulation · doi:10.1161/01.cir.0000141726.01302.83 · Cited by 171
van Melle, J. P., Bot, M., de Jonge, P., de Boer, R. A., van Veldhuisen, D. J., & Whooley, M. A. (2010) · Diabetes Care · doi:10.2337/dc10-0286 · Cited by 159
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145 · cited 1×
“All of these may, in turn, lead to thrombosis, inflammation and vulnerable coronary plaque [20].”
BackgroundTanaka, H., Takano, K., Iijima, H., Kubo, H., Maruyama, N., Hashimoto, T., Arakawa, K., Togo, M., Inagaki, N., & Kaku, K. (2017) · Advances in Therapy · doi:10.1007/s12325-016-0457-8 · Cited by 140
Dauriz, M., Targher, G., Laroche, C., Temporelli, P. L., Ferrari, R., Anker, S., Coats, A., Filippatos, G., Crespo-Leiro, M., Mebazaa, A., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2016 · Cited by 139 · cited 1×
“In fact, several large cohort studies have reported an incidence of diabetes in patients affected by HF ranging between 30% and 50%, also suggesting a mutual relationship between these two diseases [12,13].”
BackgroundGeorgianos, P. I., & Agarwal, R. (2019) · Diabetes Care · doi:10.2337/dc18-2207 · Cited by 130 · cited 1×
“SGLT2i has also been found as more effective during the night than in the daytime [116], with the particular benefit to using Empagliflozin in high-risk Asian patients with uncontrolled nocturnal hypertension [110].”
BackgroundNguyen, T., Wen, S., Gong, M., Yuan, X., Xu, D., Wang, C., Jin, J., & Zhou, L. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s258593 · Cited by 97 · cited 1×
“All those contribute to a reduction of the carotid body (CB) activation, as well as of the volume of sodium and the level of protein-bound uremic toxins, which inhibit the activation of the organum vasculosum of the lamina terminalis (OVLT) in the region of the third anteroventral ventricle (AV3V) of the hypothalamus…”
BackgroundPazin-Filho, A., Kottgen, A., Bertoni, A. G., Russell, S. D., Selvin, E., Rosamond, W. D., & Coresh, J. (2008) · Diabetologia · doi:10.1007/s00125-008-1164-z · Cited by 92
Research works printed but not linked: 122
- Shah, 2015, Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1·9 million people, Lancet Diabetes Endocrinol., 3, 105, 10.1016/S2213-8587(14)70219-0 · DOI · Paper page
- Bertoni, 2004, Heart Failure Prevalence, Incidence, and Mortality in the Elderly With Diabetes, Diabetes Care, 27, 699, 10.2337/diacare.27.3.699 · DOI · Paper page
- Gresele, 2021, Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: From the START Antiplatelet registry, Int. J. Cardiol., 327, 176, 10.1016/j.ijcard.2020.10.079 · DOI
- Zhang, 2017, Comparison of Predictors of Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Preclinical Left Ventricular Diastolic Dysfunction, Am. J. Cardiol., 119, 1815, 10.1016/j.amjcard.2017.03.005 · DOI
- Clark, 2018, In-hospital worsening heart failure: A clinically relevant endpoint?, ESC Heart Fail., 5, 9, 10.1002/ehf2.12195 · DOI
- Corrao, 2014, Gender-differences in disease distribution and outcome in hospitalized elderly: Data from the REPOSI study, Eur. J. Intern. Med., 25, 617, 10.1016/j.ejim.2014.06.027 · DOI
- Marcucci, 2016, REPOSI Investigators Defining Aging Phenotypes and Related Outcomes: Clues to Recognize Frailty in Hospitalized Older Patients, J. Gerontol. Ser. Boil. Sci. Med Sci., 72, 395
- Hwang, 2017, Effect of US Food and Drug Administration’s Cardiovascular Safety Guidance on Diabetes Drug Development, Clin. Pharmacol. Ther., 102, 290, 10.1002/cpt.705 · DOI
- Custodio, 2018, SGLT2 inhibition and heart failure—current concepts, Heart Fail. Rev., 23, 409, 10.1007/s10741-018-9703-2 · DOI
- Rubler, 1972, New type of cardiomyopathy associated with diabetic glomerulosclerosis, Am. J. Cardiol., 30, 595, 10.1016/0002-9149(72)90595-4 · DOI · Paper page
- Tate, 2017, Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat, Diabetes Vasc. Dis. Res., 14, 423, 10.1177/1479164117710390 · DOI
- Cesaro, 2020, Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition, BioFactors, 46, 367, 10.1002/biof.1619 · DOI
- Iribarren, 2001, Glycemic Control and Heart Failure Among Adult Patients With Diabetes, Circulation, 103, 2668, 10.1161/01.CIR.103.22.2668 · DOI · Paper page
- Waddingham, 2015, Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy, World J. Diabetes, 6, 943, 10.4239/wjd.v6.i7.943 · DOI · Paper page
- Qin, 2017, Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in development of diabetic cardiac complications, Pharmacol. Res., 116, 45, 10.1016/j.phrs.2016.12.016 · DOI
- Ma, 2016, Comparative Proteomics Reveals Dysregulated Mitochondrial O-GlcNAcylation in Diabetic Hearts, J. Proteome Res., 15, 2254, 10.1021/acs.jproteome.6b00250 · DOI
- Basta, 2004, Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes, Cardiovasc. Res., 63, 582, 10.1016/j.cardiores.2004.05.001 · DOI · Paper page
- Erqou, 2013, Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: Systematic review and meta-analysis, Eur. J. Heart Fail., 15, 185, 10.1093/eurjhf/hfs156 · DOI · Paper page
- Kristensen, 2017, Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation, Circ. Heart Fail., 10, 4409, 10.1161/CIRCHEARTFAILURE.117.004409 · DOI · Paper page
- Huynh, 2014, Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways, Pharmacol. Ther., 142, 375, 10.1016/j.pharmthera.2014.01.003 · DOI · Paper page
- Tate, 2017, Are targeted therapies for diabetic cardiomyopathy on the horizon?, Clin. Sci., 131, 897, 10.1042/CS20160491 · DOI
- Marfella, 2012, Tight Glycemic Control May Increase Regenerative Potential of Myocardium during Acute Infarction, J. Clin. Endocrinol. Metab., 97, 933, 10.1210/jc.2011-2037 · DOI · Paper page
- Marfella, 2012, Peri-Procedural Tight Glycemic Control during Early Percutaneous Coronary Intervention Is Associated with a Lower Rate of In-Stent Restenosis in Patients with Acute ST-Elevation Myocardial Infarction, J. Clin. Endocrinol. Metab., 97, 2862, 10.1210/jc.2012-1364 · DOI · Paper page
- Sasso, 2018, Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes, J. Diabetes Res., 2018, 1, 10.1155/2018/3106056 · DOI · Paper page
- Caturano, 2019, Metformin for Type 2 Diabetes, JAMA, 322, 1312, 10.1001/jama.2019.11489 · DOI
- Sasso, 1999, Cochlear dysfunction in type 2 diabetes: A complication independent of neuropathy and acute hyperglycemia, Metabolism., 48, 1346, 10.1016/S0026-0495(99)90141-5 · DOI · Paper page
- Sasso, 2018, Applicability of telemedicine in the screening of diabetic retinopathy (DR): The first multicentre study in Italy. The No Blind Study, Diabetes/Metabolism Res. Rev., 35, e3113, 10.1002/dmrr.3113 · DOI · Paper page
- Zhang, 2020, Oxidative stress and diabetes: Antioxidative strategies, Front. Med., 14, 583, 10.1007/s11684-019-0729-1 · DOI · Paper page
- Brancaccio, M., Mennitti, C., Cesaro, A., Fimiani, F., Moscarella, E., Caiazza, M., Gragnano, F., Ranieri, A., D’Alicandro, G., and Tinto, N. (2020). Dietary Thiols: A Potential Supporting Strategy against Oxidative Stress in Heart Failure and Muscular Damage during Sports Activity. Int. J. Environ. Res. Public Health, 17. · DOI
- Huynh, 2013, Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice, Free. Radic. Biol. Med., 60, 307, 10.1016/j.freeradbiomed.2013.02.021 · DOI
- Packer, 2018, Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis, Diabetes Obes. Metab., 20, 1361, 10.1111/dom.13229 · DOI · Paper page
- Hsieh, 2014, Shear-induced endothelial mechanotransduction: The interplay between reactive oxygen species (ROS) and nitric oxide (NO) and the pathophysiological implications, J. Biomed. Sci., 21, 3, 10.1186/1423-0127-21-3 · DOI · Paper page
- Kumrić, M., Borovac, J., Kurir, T., and Božić, J. (2021). Clinical Implications of Uric Acid in Heart Failure: A Comprehensive Review. Life, 11. · DOI
- Zafar, 2019, Metabolism of the failing heart and the impact of SGLT2 inhibitors, Expert Opin. Drug Metab. Toxicol., 15, 275, 10.1080/17425255.2019.1588886 · DOI
- Lopaschuk, 2010, Myocardial Fatty Acid Metabolism in Health and Disease, Physiol. Rev., 90, 207, 10.1152/physrev.00015.2009 · DOI · Paper page
- Landa, 1999, Effects of Autonomic Neuropathy on Coronary Blood Flow in Patients With Diabetes Mellitus, Circulation, 100, 813, 10.1161/01.CIR.100.8.813 · DOI · Paper page
- Masuo, 2010, Cardiovascular and renal complications of type 2 diabetes in obesity: Role of sympathetic nerve activity and insulin resistance, Curr. Diabetes Rev., 6, 58, 10.2174/157339910790909396 · DOI · Paper page
- Thomas, 2016, Type 2 Diabetes and Heart Failure: Challenges and Solutions, Curr. Cardiol. Rev., 12, 249, 10.2174/1573403X12666160606120254 · DOI · Paper page
- Campbell, 2011, Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease, Cardiovasc. Diabetol., 10, 80, 10.1186/1475-2840-10-80 · DOI · Paper page
- Cozzolino, 1996, The involvement of the opioid system in human obesity: A study in normal weight relatives of obese people, J. Clin. Endocrinol. Metab., 81, 713
- Cozzolino, 2004, Acute effects of β-endorphin on cardiovascular function in patients with mild to moderate chronic heart failure, Am. Heart J., 148, 530, 10.1016/j.ahj.2004.01.029 · DOI
- Khan, 2014, Management of Comorbid Diabetes Mellitus and Worsening Heart Failure, JAMA, 311, 2379, 10.1001/jama.2014.4115 · DOI
- Swoboda, P.P., McDiarmid, A.K., Erhayiem, B., Ripley, D.P., Dobson, L.E., Garg, P., Musa, T.A., Witte, K.K., Kearney, M.T., and Barth, J.H. (2017). Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure. J. Am. Heart Assoc., 6. · DOI · Paper page
- Zelniker, 2020, Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors, J. Am. Coll. Cardiol., 75, 422, 10.1016/j.jacc.2019.11.031 · DOI · Paper page
- Lenti, 2019, Mortality rate and risk factors for gastrointestinal bleeding in elderly patients, Eur. J. Intern. Med., 61, 54, 10.1016/j.ejim.2018.11.003 · DOI
- Aubert, 2016, The Failing Heart Relies on Ketone Bodies as a Fuel, Circulation, 133, 698, 10.1161/CIRCULATIONAHA.115.017355 · DOI · Paper page
- Sowton, 2019, Metabolic Profiling of the Diabetic Heart: Toward a Richer Picture, Front. Physiol., 10, 639, 10.3389/fphys.2019.00639 · DOI
- Nielsen, 2019, Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients, Circulation, 139, 2129, 10.1161/CIRCULATIONAHA.118.036459 · DOI · Paper page
- Horton, 2019, The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense, JCI Insight, 4, 124079, 10.1172/jci.insight.124079 · DOI · Paper page
- Rajeev, 2015, SGLT2 inhibition and ketoacidosis—should we be concerned?, Br. J. Diabetes Vasc. Dis., 15, 155, 10.15277/bjdvd.2015.047 · DOI
- Verma, 2018, Empagliflozin Increases Cardiac Energy Production in Diabetes, JACC Basic Transl. Sci., 3, 575, 10.1016/j.jacbts.2018.07.006 · DOI · Paper page
- Daniele, 2017, Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients, Diabetes Obes. Metab., 19, 809, 10.1111/dom.12881 · DOI
- Antonio, 2019, Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics, J. Am. Coll. Cardiol., 73, 1931, 10.1016/j.jacc.2019.01.056 · DOI · Paper page
- Kappel, 2017, Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease, Circulation, 136, 969, 10.1161/CIRCULATIONAHA.117.029166 · DOI
- Goonasekera, 2012, Decreased cardiac L-type Ca2+ channel activity induces hypertrophy and heart failure in mice, J. Clin. Investig., 122, 280, 10.1172/JCI58227 · DOI · Paper page
- Lytvyn, 2017, Sodium Glucose Cotransporter-2 Inhibition in Heart Failure, Circulation, 136, 1643, 10.1161/CIRCULATIONAHA.117.030012 · DOI · Paper page
- Lambert, 2015, Intracellular Na + Concentration ([Na + ] i) Is Elevated in Diabetic Hearts Due to Enhanced Na+ Glucose Cotransport, J. Am. Heart Assoc., 4, e002183, 10.1161/JAHA.115.002183 · DOI · Paper page
- Kohlhaas, 2010, Elevated Cytosolic Na+ Increases Mitochondrial Formation of Reactive Oxygen Species in Failing Cardiac Myocytes, Circulation, 121, 1606, 10.1161/CIRCULATIONAHA.109.914911 · DOI · Paper page
- Banerjee, 2009, SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states, Cardiovasc. Res., 84, 111, 10.1093/cvr/cvp190 · DOI · Paper page
- Baartscheer, 2017, Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits, Diabetologia, 60, 568, 10.1007/s00125-016-4134-x · DOI · Paper page
- Uthman, 2018, Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation, Diabetologia, 61, 722, 10.1007/s00125-017-4509-7 · DOI · Paper page
- Packer, 2017, Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients with Heart Failure, JAMA Cardiol., 2, 1025, 10.1001/jamacardio.2017.2275 · DOI · Paper page
- Karmazyn, 2013, NHE-1: Still a viable therapeutic target, J. Mol. Cell. Cardiol., 61, 77, 10.1016/j.yjmcc.2013.02.006 · DOI
- Krishnan, 2009, Hyperuricemia and Incident Heart Failure, Circ. Heart Fail., 2, 556, 10.1161/CIRCHEARTFAILURE.108.797662 · DOI
- Saydah, 2004, Poor Control of Risk Factors for Vascular Disease among Adults With Previously Diagnosed Diabetes, JAMA, 291, 335, 10.1001/jama.291.3.335 · DOI · Paper page
- Ghantous, 2015, Differential Role of Leptin and Adiponectin in Cardiovascular System, Int. J. Endocrinol., 2015, 1, 10.1155/2015/534320 · DOI · Paper page
- Sasso, 2019, Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: The prospective AIRE Study, Cardiovasc. Diabetol., 18, 1, 10.1186/s12933-019-0826-0 · DOI · Paper page
- Schulze, 2003, Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure, Eur. J. Heart Fail., 5, 33, 10.1016/S1388-9842(02)00177-0 · DOI · Paper page
- Wu, 2019, Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes, Horm. Metab. Res., 51, 487, 10.1055/a-0958-2441 · DOI · Paper page
- Garvey, 2018, Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes, Metabolism., 85, 32, 10.1016/j.metabol.2018.02.002 · DOI · Paper page
- Sato, 2018, The effect of dapagliflozin treatment on epicardial adipose tissue volume, Cardiovasc. Diabetol., 17, 1, 10.1186/s12933-017-0658-8 · DOI · Paper page
- Esposito, 2007, Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: Role of tumor necrosis factor-α, Nutr. Metab. Cardiovasc. Dis., 17, 274, 10.1016/j.numecd.2005.11.014 · DOI
- Marfella, 2007, The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes, Cardiovasc. Diabetol., 6, 35, 10.1186/1475-2840-6-35 · DOI · Paper page
- Marfella, 2011, Innate Immune Activity in Plaque of Patients with Untreated andl-Thyroxine-Treated Subclinical Hypothyroidism, J. Clin. Endocrinol. Metab., 96, 1015, 10.1210/jc.2010-1382 · DOI · Paper page
- Torella, 2014, Carbonic Anhydrase Activation Is Associated With Worsened Pathological Remodeling in Human Ischemic Diabetic Cardiomyopathy, J. Am. Heart Assoc., 3, e000434, 10.1161/JAHA.113.000434 · DOI · Paper page
- Storgaard, H., Gluud, L.L., Bennett, C., Grøndahl, M.F., Christensen, M.B., Knop, F.K., and Vilsbøll, T. (2016). Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS ONE, 11. · DOI · Paper page
- Tsimihodimos, 2018, SGLT-2 inhibitors: Pharmacokinetics characteristics and effects on lipids, Expert Opin. Drug Metab. Toxicol., 14, 1
- Haffner, 2003, American Diabetes Association Management of Dyslipidemia in Adults with Diabetes, Diabetes Care, 26, S83, 10.2337/diacare.26.2007.S83 · DOI · Paper page
- Zaccardi, 2016, Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis, Diabetes Obes. Metab., 18, 783, 10.1111/dom.12670 · DOI · Paper page
- Moscarella, 2019, Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry), Am. J. Cardiol., 124, 1662, 10.1016/j.amjcard.2019.08.030 · DOI
- Lopaschuk, 2020, Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors, JACC Basic Transl. Sci., 5, 632, 10.1016/j.jacbts.2020.02.004 · DOI · Paper page
- Gharaibeh, 2019, SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: Pathophysiology, clinical outcomes, and future directions, Diabetes Metab. Syndr. Obesity Targets Ther., 12, 1001, 10.2147/DMSO.S212715 · DOI
- Scheen, 2019, Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications, Diabetes Metab., 45, 213, 10.1016/j.diabet.2019.01.008 · DOI · Paper page
- Targher, 2020, NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications, Gut, 69, 1691, 10.1136/gutjnl-2020-320622 · DOI · Paper page
- Rinaldi, 2015, Effect of anti-oxidant agents in patients with hepato-cellular diseases, Eur. Rev. Med. Pharmacol. Sci., 19, 3993
- Rinaldi, 2016, Antioxidant diet and genotyping as tools for the prevention of liver disease, Eur. Rev. Med Pharmacol. Sci., 20, 5155
- Tromp, 2019, Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction, Diabetes Care, 42, 1792, 10.2337/dc18-2515 · DOI
- Zelniker, 2020, Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors, J. Am. Coll. Cardiol., 75, 435, 10.1016/j.jacc.2019.11.036 · DOI
- Baker, 2017, Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis, J. Am. Heart Assoc., 6, e005686, 10.1161/JAHA.117.005686 · DOI · Paper page
- Solini, 2017, Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: A pilot study, Cardiovasc. Diabetol., 16, 1, 10.1186/s12933-017-0621-8 · DOI · Paper page
- Sugiyama, 2018, The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus, Intern. Med., 57, 2147, 10.2169/internalmedicine.0701-17 · DOI
- Tentolouris, 2020, Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice, Curr. Med. Chem., 27, 1089, 10.2174/0929867326666190119154152 · DOI
- Striepe, 2017, Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus, Circulation, 136, 1167, 10.1161/CIRCULATIONAHA.117.029529 · DOI · Paper page
- Ott, 2017, A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation, Cardiovasc. Diabetol., 16, 26, 10.1186/s12933-017-0510-1 · DOI · Paper page
- Karg, 2018, SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: A randomised controlled trial, Cardiovasc. Diabetol., 17, 1, 10.1186/s12933-017-0654-z · DOI · Paper page
- Kimura, 2016, Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure, Circ. J., 80, 2277, 10.1253/circj.CJ-16-0780 · DOI · Paper page
- Giordano, 2017, Seasonal variations of hyponatremia in the emergency department: Age-related changes, Am. J. Emerg. Med., 35, 749, 10.1016/j.ajem.2017.01.018 · DOI
- Verma, 2017, The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition, JAMA Cardiol., 2, 939, 10.1001/jamacardio.2017.1891 · DOI · Paper page
- Sattar, 2016, SGLT2 Inhibition and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms?, Diabetologia, 59, 1333, 10.1007/s00125-016-3956-x · DOI · Paper page
- Aoyagi, T., and Matsui, T. (2012). The Cardiomyocyte as a Source of Cytokines in Cardiac Injury. J. Cell Sci. Ther., s5. · DOI
- Xu, 2017, SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice, EBioMedicine, 20, 137, 10.1016/j.ebiom.2017.05.028 · DOI · Paper page
- Bonnet, 2018, Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease, Diabetes Metab., 44, 457, 10.1016/j.diabet.2018.09.005 · DOI · Paper page
- Paulus, 2020, Unfolding Discoveries in Heart Failure, N. Engl. J. Med., 382, 679, 10.1056/NEJMcibr1913825 · DOI · Paper page
- Schiattarella, 2019, Nitrosative stress drives heart failure with preserved ejection fraction, Nat. Cell Biol., 568, 351
- Lee, 2017, Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts, Free. Radic. Biol. Med., 104, 298, 10.1016/j.freeradbiomed.2017.01.035 · DOI · Paper page
- Kang, 2020, Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results, Can. J. Cardiol., 36, 543, 10.1016/j.cjca.2019.08.033 · DOI · Paper page
- Lim, 2009, AMPK as a mediator of hormonal signalling, J. Mol. Endocrinol., 44, 87, 10.1677/JME-09-0063 · DOI · Paper page
- Lu, 2020, Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway, Mol. Cell. Endocrinol., 501, 110642, 10.1016/j.mce.2019.110642 · DOI
- Li, 2019, SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart, Cardiovasc. Diabetol., 18, 1, 10.1186/s12933-019-0816-2 · DOI · Paper page
- Chen, 2020, The association between SGLT2 inhibitors and new-onset arrhythmias: A nationwide population-based longitudinal cohort study, Cardiovasc. Diabetol., 19, 73, 10.1186/s12933-020-01048-x · DOI
- Santulli, 2018, Cardioprotective effects of autophagy: Eat your heart out, heart failure!, Sci. Transl. Med., 10, 462, 10.1126/scitranslmed.aau0462 · doi:10.1126/scitranslmed.aau0462
- Luo, 2019, Sirt1 promotes autophagy and inhibits apoptosis to protect cardiomyocytes from hypoxic stress, Int. J. Mol. Med., 43, 2033
- Packer, 2020, Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors, Eur. J. Heart Fail., 22, 618, 10.1002/ejhf.1732 · DOI
- Hawley, 2016, The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels, Diabetes, 65, 2784, 10.2337/db16-0058 · DOI · Paper page
- Wilding, 2018, SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice, Diabetes Ther., 9, 1757, 10.1007/s13300-018-0471-8 · DOI · Paper page
- Figtree, 2018, Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus, Circulation, 138, 458, 10.1161/CIRCULATIONAHA.118.034222 · DOI · Paper page
- Coats, 2020, European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure, Eur. J. Heart Fail., 22, 196, 10.1002/ejhf.1673 · DOI · Paper page
- Fragasso, 2020, Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure, Eur. J. Heart Fail., 22, 1984, 10.1002/ejhf.2026 · DOI
- Mancini, 2021, Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction, J. Am. Coll. Cardiol., 77, 243, 10.1016/j.jacc.2020.11.008 · DOI · Paper page
- Damman, 2020, Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF), Eur. J. Heart Fail., 22, 713, 10.1002/ejhf.1713 · DOI · Paper page
- Anker, 2019, Evaluation of the effects of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: Rationale for and design of the EMPEROR-Preserved Trial, Eur. J. Heart Fail., 21, 1279, 10.1002/ejhf.1596 · DOI · Paper page
- Minutolo, 2018, Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: Pooled analysis of four cohort studies, Nephrol. Dial. Transplant., 33, 1942, 10.1093/ndt/gfy032 · DOI · Paper page
Cited by
Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications
Caturano, A., D’Angelo, M., Mormone, A., Russo, V., Mollica, M. P., Salvatore, T., Galiero, R., Rinaldi, L., Vetrano, E., Marfella, R., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45080420 · Cited by 579
Self-citationSalvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62
Self-citationSGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation
Liu, W., You, D., Lin, J., Zou, H., Zhang, L., Luo, S., Yuan, Y., Wang, Z., Qi, J., Wang, W., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.08.005 · Cited by 61
Metadata
- Authors
- Palmiero, G., Cesaro, A., Vetrano, E., Pafundi, P. C., Galiero, R., Caturano, A., Moscarella, E., Gragnano, F., Salvatore, T., Rinaldi, L., Calabrò, P., & Sasso, F. C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-05-30
- Volume
- 22
- Issue
- 11
- Pages
- 5863
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3165814139
- Cited by
- 110
- References
- 48
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.